Awakn Life Sciences Files Patent Applications In U.S. For AWKN001 And AWKN002, Two Next- Generation New Chemical Entities [NCEs] To Treat A Broad Range Of Addiction Indications

Broadening of intellectual property portfolio for these two NCEs clearly defines development pathway for the next generation of psychedelic medicines to treat addiction TORONTO, CANADA, 28 June 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today announced the filing…

Source